Monitoring Monoclonal Gammopathies
Back to Search Results
Test Utilization
Introduction
November 2009
This presentation is provided by Dr. Jerry Katzmann, from the Division of Clinical Biochemistry and Immunology at Mayo Clinic. Dr. Katzmann will be discussing the 2009 Guidelines for Disease Monitoring from the International Myeloma Working Group.
With the introduction of the quantitative free light chain assay, the guidelines for monitoring monoclonal gammopathies have recently changed. This presentation will review the current laboratory practice for monitoring monoclonal gammopathies.
Introduction |
Jump to section:
- Slide Images
- International Myeloma Working Group: Disease Monitoring
- Serum Protein Electrophoresis and Immunofixation Electrophoresis
- Serum and Urine Protein Electrophoresis and Immunofixation Electrophoresis
- Methods for Monitoring Monoclonal Gammopathies: 2005 IMWG
- Methods for Monitoring Monoclonal Gammopathies
- Small IgG kappa M-spike
- Large IgG kappa M-spike
- Relationship of Serum Agarose Electrophoresis M-spike and Ig Quantitation1
- Disease Monitoring
- Monoclonal Gammopathies: Primary Systemic Amyloidosis
- Free Light Chain: Antibody Specificity
- FLC κ/λ Ratio: Disease Sensitivity2
- Methods for Monitoring Monoclonal Gammopathies
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring3
- Response Criteria for FLC4,5
- Receiver Operator Curve (ROC): % FLC Reduction vs. Overall Hematologic Response6
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document